Corporate deck highlights IFx-2.0 and TBS-2025 programs
Tuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 in first-line metastatic Merkel cell carcinoma.
The trial targets about 118 patients, with topline data expected in the second half of 2027; the design uses ORR as the primary endpoint and PFS as the key secondary endpoint.
The program runs under an FDA Special Protocol Assessment, and a confirmatory trial is not expected to be required.
Tuhura plans to start a Phase 1b/2 trial of the VISTA-inhibiting antibody TBS-2025 in mutNPM1 relapsed or refractory AML in the second half of 2026.
The company cited a $50 million credit facility and royalty transaction, projecting an operating runway through Q1 2028.
HURA•
